CADDAC_logo-FULL-tagline-ENG
CADDAC_logo-FULL-ENG

MULTI-CENTER, OPEN LABEL EVALUATION OF THE EFFECT AND SAFETY OF LISDEXAMFETAMINE (VYVANSE) IN CHILDREN AGED 6-12 WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER AND AUTISM SPECTRUM DISORDER

10/11/2021
Shelly-Ann McMorris

Purpose of Research:
If your child has ADHD and autism, you are aware that these conditions can be difficult to diagnose and manage. This study is researching a Health Canada-approved medication called Vyvanse, to find out how it works in children 6 to 12 years of age with ADHD and autism.

Who Can Participate?
Boys and girls, 6-12 years of age with a diagnosis of both ADHD and ASD-level 1, who can attend in-person appointments in Ottawa, Ontario.

What is involved?
Eligible participants will be seen by a doctor and receive all study-related exams, care, and medications at no cost. Your child will be in the study for about 3 months, with 7 on-site appointments in Ottawa, Ontario. The medication will be prescribed by the study doctor, and your child will take it once a day. Your child will have regular check-ups with the doctor to determine how the medication is working and evaluate any possible side effects. Your doctor may continue to prescribe this medication upon completion of the study. Reimbursement for study-related travel and expenses is available.

Location of Study:
Center for Pediatric Excellence
206-1637 Woodroffe Ave.
Ottawa, ON, K2G 1W2

How Can I Join This Study?
To find out more information and/or to see if your child may be eligible, contact the study coordinator or visit https://drvanstralen.ca/landing-page-vyvanse-study/.

Contact Information:
Suzannah Wojcik, CCRP
Clinical Research Coordinator
Phone: 613-726-7355

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram